Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT01802021

Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients (QSYQT)

Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy

Sponsor: Chang Gung Memorial Hospital

Conditions Carcinoma, Non-Small-Cell Lung

Interventions Astagalus-based Formula: Qingshu-Yiqi-Tang

Updated 5 times since 2017 Last updated: Feb 28, 2013 Started: May 31, 2009 Primary completion: Dec 31, 2013 Completion: Feb 28, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01802021, this PHASE2/PHASE3 trial focuses on Carcinoma, Non-Small-Cell Lung and remains ongoing. Sponsored by Chang Gung Memorial Hospital, it has been updated 5 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chang Gung Memorial Hospital

Data source: Chang Gung Memorial Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gueishan Township, Taiwan